- Earlier this year, DaVita reported quarterly results with revenue and adjusted EPS above analyst expectations, underscoring strong execution in its Integrated Kidney Care business.
- At the same time, DaVita’s value-based kidney care programs, including the CKCC initiative, have generated over US$200 million in shared savings while improving patient outcomes.
- Now we’ll examine how DaVita’s CKCC-driven value-based care progress may influence its existing investment narrative and future expectations.
AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
DaVita Investment Narrative Recap
To own DaVita, you need to believe that stable dialysis demand and expanding value based care can support consistent earnings, despite reimbursement and volume pressures. The latest CKCC results, with over US$200 million in shared savings, reinforce the near term catalyst around Integrated Kidney Care credibility, but do not materially reduce the key risk that treatment volumes and mortality trends could still cap growth and pressure margins.
The most relevant recent development here is DaVita’s February earnings, where revenue and adjusted EPS came in ahead of analyst expectations. That upside was tied partly to disciplined execution in Integrated Kidney Care, which gives more weight to the idea that value based programs like CKCC could become a meaningful earnings contributor over time, even as the core dialysis business contends with reimbursement and cost pressures.
Yet, despite this progress, investors should still watch how persistent volume pressure and reimbursement updates could affect DaVita’s earnings power over time...
Read the full narrative on DaVita (it's free!)
DaVita's narrative projects $15.0 billion revenue and $970.4 million earnings by 2028. This requires 4.4% yearly revenue growth and about a $134 million earnings increase from $836.3 million today.
Uncover how DaVita's forecasts yield a $151.71 fair value, in line with its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts took a much more cautious view, assuming revenue of about US$15.3 billion and earnings near US$803 million by 2029, and highlighting how volatile Integrated Kidney Care income and payer mix uncertainty could still reshape DaVita’s story in light of the new CKCC results.
Explore 2 other fair value estimates on DaVita - why the stock might be worth just $151.71!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your DaVita research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free DaVita research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DaVita's overall financial health at a glance.
Searching For A Fresh Perspective?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
- The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com